EG 005

Drug Profile

EG 005

Alternative Names: EG005

Latest Information Update: 09 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Unknown
  • Class Small molecules
  • Mechanism of Action Angiotensin receptor antagonists; Mitochondrial protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Lipodystrophy

Most Recent Events

  • 07 Mar 2007 Discontinued - Phase-II for Lipodystrophy in United Kingdom (PO)
  • 05 Sep 2006 Initial results from a extension study of a phase II trial in lipodystrophy have been added to the Cancer therapeutic trials section
  • 30 Aug 2006 Ark Therapeutics has completed a 1-year voluntary extension study of a phase II trial in lipodystrophy in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top